Iris Xie
Overview
Explore the profile of Iris Xie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie I, Choi W, Wang S, Lee H, Hong B, Wang N, et al.
J Imaging
. 2024 Aug;
10(8).
PMID: 39194994
While it is common for blind and visually impaired (BVI) users to use mobile devices to search for information, little research has explored the accessibility issues they encounter in their...
2.
Anderson M, Dockendorf M, McIntosh I, Xie I, Breidinger S, Meng D, et al.
AAPS J
. 2022 Apr;
24(3):52.
PMID: 35384529
In-clinic dried blood spot (DBS) pharmacokinetic (PK) sampling was incorporated into two phase 3 studies of verubecestat for Alzheimer's disease (EPOCH [NCT01739348] and APECS [NCT01953601]), as a potential alternative to...
3.
Li C, Voss T, Kowalski K, Yang B, Kleijn H, Jones C, et al.
Clin Transl Sci
. 2019 Nov;
13(3):482-490.
PMID: 31758661
Ubrogepant (MK-1602) is a novel, oral, calcitonin gene-related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure-response...
4.
Sun L, Chavez-Eng C, Fillgrove K, Lu B, Xie I, Jackson Rudd D, et al.
Bioanalysis
. 2019 Feb;
11(4):233-250.
PMID: 30767560
MK-8591 (EFdA), a novel anti-HIV nucleoside analog, is converted to mono-, di- and tri-phosphates (MK-8591-MP, MK-8591-DP and MK-8591-TP) intracellularly, among which MK-8591-TP is the active pharmacological form. An ultrasensitive LC-MS/MS...
5.
Xu Y, Goykhman D, Wang M, Jackson T, Xie I, Willson K, et al.
Bioanalysis
. 2018 Aug;
10(15):1207-1220.
PMID: 30062907
Advances in technology have led to a shift for peptide quantification from traditional ligand-binding assays to LC-MS/MS-based analysis, which presents challenges, in other assay sensitivity, specificity and ruggedness, in addition...
6.
Dockendorf M, Murthy G, Bateman K, Kothare P, Anderson M, Xie I, et al.
Clin Pharmacol Ther
. 2018 Jun;
105(1):168-176.
PMID: 29885208
Merck & Co, Inc (Kenilworth, NJ) is investing in approaches to enrich clinical trial data and augment decision making through use of digital health technologies, outpatient sampling, and real-time data...
7.
Xie I, Xu Y, Anderson M, Wang M, Xue L, Breidinger S, et al.
J Pharm Biomed Anal
. 2018 Apr;
156:58-66.
PMID: 29689469
Volumetric absorptive microsampling (VAMS), a new microsampling technique, was evaluated for its potential in supporting regulated bioanalysis. Our initial assessment with MK-0518 (raltegravir) using a direct extraction method resulted in...
8.
Li C, Dockendorf M, Kowalski K, Yang B, Xu Y, Xie I, et al.
J Clin Pharmacol
. 2017 Nov;
58(3):294-303.
PMID: 29136283
Merck & Co., Inc. (Kenilworth, New Jersey) has recently published an integrated strategy for implementation of dried blood spots (DBS) in late-stage trials for population pharmacokinetic (PK) modeling. We applied...